Autopsy report · NCT02581501

Prospective Phase I Study of GAX for Metastatic Pancreatic Cancer

“Due to no enrollment, Celgene (sponsor) withdrew funding”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

Stamford Hospital

Sponsor type

University, hospital or other

Conditions

Pancreatic Cancer

Interventions

GAX - Gemcitabine, Abraxane and Xeloda

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• 129Xe Gas Exchange Imaging in IPF and cHP: A Reliability Study
  “Sponsor withdrew Funding” (75% match in meaning)
• Lucentis for New Onset Neovascular Glaucoma
  “Company withdrew funding/sponsorship” (73% match in meaning)
• Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma
  “Funding withdrawn by sponsor” (73% match in meaning)
• A Safety and Efficacy Study of Alefacept in the Treatment of Moderate to Severe Erosive Mucosal Lichen Planus
  “Pharmaceutical sponsor withdrew financial support.” (72% match in meaning)
• Pasireotide in Hyperinsulinemic Hypoglycemia
  “Funding was withdrawn by Sponsor prior to start of study” (72% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.